Central Dogma of Molecular Biology: DNA to RNA to Protein

Messenger RNA (mRNA) undergoes three essential post-transcriptional modifications in the nucleus before exiting to the cytoplasm for protein synthesis: (1) the addition of a 5' guanosine triphosphate cap that protects mRNA from degradation and enables nuclear export, (2) polyadenylation of the 3' end by adding 200-250 adenosine nucleotides to provide stability and aid transport, and (3) splicing where introns are removed and exons are joined together by the spliceosome complex to form the mature mRNA molecule.

RNA splicing is a post-transcriptional modification that removes non-coding introns from pre-mRNA to produce mature mRNA, involving three types: Group 1 self-splicing (RNA-catalyzed without proteins), Group 2 self-splicing (RNA-catalyzed with lariat formation), and Group 3 spliceosome-mediated splicing (protein-RNA complex with U1, U2, U4, U5, U6 snRNPs and auxiliary factors that recognize splice sites and catalyze the reaction through nucleophilic attack at the branch point).

After transcription, pre-mRNA undergoes three modifications: 5' capping (addition of 7-methylguanosine cap), 3' poly-A tail addition (long chain of adenine nucleotides), and splicing (removal of introns and ligation of exons by spliceosomes/snRNPs). These modifications occur in the nucleus before mRNA exits to the cytoplasm for translation.

After transcription, pre-mRNA undergoes three key modifications: 5' capping (addition of 7-methylguanosine cap), 3' poly-A tail addition (long chain of adenine residues), and splicing (removal of introns and ligation of exons by spliceosomes/snRNPs). These modifications are essential for mRNA stability, nuclear export, and translation efficiency.

RNA splicing is the process of removing introns and joining exons in eukaryotic mRNA, performed by the spliceosome (a complex of snRNA and proteins). This process is absent in prokaryotes because they lack introns and snRNA. Post-transcriptional modification in eukaryotes includes terminal trimming, 5' capping (7-methylguanosine cap), poly-A tail addition (200-300 adenine residues), and splicing. The 5' cap protects mRNA from degradation and aids in translation initiation, while the poly-A tail facilitates nuclear export. The RNA world hypothesis suggests RNA was the first genetic material because it can catalyze its own processing and form both DNA and proteins.

Point mutations involve changes to single nucleotide bases and include deletion (removal of one nucleotide), insertion (addition of one nucleotide), and substitution (replacement of one nucleotide with another). Deletions and insertions cause frameshift mutations that alter all subsequent codons, potentially changing all amino acids downstream and severely affecting protein function. Substitutions replace one nucleotide with another and can be silent (no amino acid change), missense (one amino acid change), or nonsense (creates stop codon). Unlike deletions and insertions, substitutions typically affect only one amino acid.

This section covers molecular-level mutations: (1) Point mutations (deletions, insertions, substitutions) and their effects on reading frames, (2) Classification of substitution mutations (silent, missense, nonsense), (3) The genetic code with codons specifying amino acids, (4) Mutagenic agents (physical and chemical) that cause mutations. Understanding these mechanisms explains how single nucleotide changes can alter protein function and cause disease.

Gene mutations occur through insertion (adding nucleotides), deletion (removing nucleotides), or substitution (replacing nucleotides). Substitution includes transition (purine-purine or pyrimidine-pyrimidine change) and transversion (purine-pyrimidine change). These mutations alter the genetic code at the molecular level and can affect gene function.

Gene mutations are classified by molecular changes: (1) Base substitutions - transitions (purine to purine or pyrimidine to pyrimidine) and transversions (purine to pyrimidine or vice versa); (2) Frameshift mutations - insertions or deletions of base pairs that shift the reading frame. These molecular changes determine the downstream effects on protein structure and function.

This extensive section details the classification and consequences of gene mutations. Frameshift mutations (insertions/deletions of nucleotide pairs) shift the reading frame, producing completely different amino acid sequences and non-functional proteins. These underlie neurodegenerative diseases like Huntington's disease (CAG trinucleotide repeat expansion causing abnormally long huntingtin protein) and ALS (GGGGCC hexanucleotide expansion). Substitution mutations replace one base with another, producing transitions (purine-purine or pyrimidine-pyrimidine) and transversions (purine-pyrimidine). Missense mutations substitute amino acids with chemically similar ones (less severe effects) or different ones (major structural changes), as seen in sickle cell anemia (glutamic acid→valine). Nonsense mutations convert codons to stop signals (TAA, TAG, TGA), producing truncated non-functional proteins. Cystic fibrosis exemplifies this with nonsense mutations in the CFTR gene (chromosome 7, 1,480 amino acids) causing severe pulmonary and pancreatic disease depending on tissue-specific absence of functional protein.

PCR (Polymerase Chain Reaction) is a fundamental molecular biology technique used to amplify specific DNA regions from small initial samples, enabling applications in genetic reconstruction, mitochondrial DNA analysis, gene transfer detection, early disease diagnosis, gene expression quantification, rapid infection diagnosis, embryo sex determination, prenatal diagnosis of genetic disorders like sickle cell anemia, and monitoring retroviral infections such as HIV.

This section covers molecular biology techniques and applications. RNA interference (RNAi) is a natural cellular defense mechanism where double-stranded RNA triggers gene silencing through the RNA-induced silencing complex (RISC), which degrades complementary mRNA sequences. Recombinant insulin is produced by inserting human insulin genes into bacterial cells, involving DNA synthesis, chain separation, bacterial production, and chemical linking with C-peptide removal. Gene therapy corrects genetic defects by inserting normal functional genes into cells, potentially providing permanent cures for genetic disorders, especially when performed during embryonic stages. These techniques revolutionize medical diagnostics and therapeutic development.

Molecular diagnosis enables early disease detection using techniques like PCR and recombinant DNA technology. Gene therapy involves correcting genetic defects in somatic cells after birth, not in embryos. The first clinical gene therapy (1990) treated SCID by introducing functional ADA genes. These applications demonstrate biotechnology's potential in medicine.

PCR (Polymerase Chain Reaction) amplifies specific DNA fragments through thermal cycling, using heat-stable polymerase from thermophilic bacteria. Each cycle doubles DNA, producing millions of copies in hours. DNA recombinant technology combines genes from different species (e.g., human insulin gene in bacteria). Gene therapy uses viral vectors to deliver therapeutic genes. These techniques enable forensic DNA analysis, medical diagnostics, and production of therapeutic proteins like insulin.

This section covers biotechnology applications. PCR uses three steps: denaturation, annealing, and extension. Taq polymerase from Thermus aquaticus withstands high temperatures. Vent polymerase from Thermococcus litoralis is another heat-stable alternative. Bt toxin exists as inactive protoxin activated in alkaline insect gut environments. RNA interference controls tobacco root nematode by silencing genes. The first gene therapy (1990) treated ADA deficiency by replacing defective genes. These applications demonstrate how molecular biology tools solve practical problems in medicine and agriculture.